Perazella M A, Cayco A V
Yale University School of Medicine, Section of Nephrology, LMP 2071, 333 Cedar Street, New Haven, CT 06520-8029, USA.
Am J Ther. 1998 Nov;5(6):399-403. doi: 10.1097/00045391-199811000-00008.
Intravenous immune globulin (IVIG) therapy has been used more commonly to treat a number of clinical disorders. During the past 10 years, IVIG infusion has been associated with a variety of complications. Acute renal failure, which was not described in the initial drug trials, was recognized as an adverse effect of IVIG therapy in 1987. Since the original report, a number of cases have been described in the literature. Older age and preexisting renal impairment appear to predispose to the development of acute renal failure. Acute renal insufficiency develops within days and resolves over several days to weeks. However, in some cases, recovery is delayed and initiation of renal replacement therapy is required. Chronic renal insufficiency requiring maintenance dialysis is extremely rare. The precise cause of IVIG-associated acute renal failure is unknown but may be attributable to either the direct effects of the immunoglobulin or the stabilizing agent used in the IVIG preparation.
静脉注射免疫球蛋白（IVIG）疗法已更广泛地用于治疗多种临床疾病。在过去10年中，IVIG输注与多种并发症相关。急性肾衰竭在最初的药物试验中未被描述，1987年被确认为IVIG治疗的一种不良反应。自最初报告以来，文献中已描述了许多病例。年龄较大和既往存在肾功能损害似乎易发生急性肾衰竭。急性肾功能不全在数天内发展，并在数天至数周内缓解。然而，在某些情况下，恢复延迟，需要开始肾脏替代治疗。需要维持性透析的慢性肾功能不全极为罕见。IVIG相关急性肾衰竭的确切原因尚不清楚，但可能归因于免疫球蛋白的直接作用或IVIG制剂中使用的稳定剂。
